Core Viewpoint - Tongyuan Kang Pharmaceutical-B (02410) has seen its stock rise nearly 5% in the afternoon trading session, currently up 3.65% at HKD 13.06, with a trading volume of HKD 28.9062 million. The company announced that its investigational first-class new drug, TY-9591 (Axitinib), has been included in the priority review list by the National Medical Products Administration (NMPA) [1][1]. Group 1 - The drug TY-9591 is intended for the first-line treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) who have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 substitution mutations, along with central nervous system metastases [1][1]. - Inclusion in the priority review list signifies an acceleration in the review process for TY-9591, potentially leading to an earlier market launch and providing new treatment options for patients in China [1][1].